Display options
Cite
Codère F, Brais B, Rouleau G, et al. Oculopharyngeal muscular dystrophy: What's new?. Orbit. 2001;20(4):259-266doi: 10.1076/orbi.20.4.259.2617.
Codère, F., Brais, B., Rouleau, G., & Lafontaine, E. (2001). Oculopharyngeal muscular dystrophy: What's new?. Orbit (Amsterdam, Netherlands), 20(4), 259-266. https://doi.org/10.1076/orbi.20.4.259.2617
Codère, François, et al. "Oculopharyngeal muscular dystrophy: What's new?." Orbit (Amsterdam, Netherlands) vol. 20,4 (2001): 259-266. doi: https://doi.org/10.1076/orbi.20.4.259.2617
Codère F, Brais B, Rouleau G, Lafontaine E. Oculopharyngeal muscular dystrophy: What's new?. Orbit. 2001 Dec;20(4):259-266. doi: 10.1076/orbi.20.4.259.2617. PMID: 12045902.
Copy Download .nbib Format: NLM
Share it on

Orbit. 2001 Dec;20(4):259-266. doi: 10.1076/orbi.20.4.259.2617.

Oculopharyngeal muscular dystrophy: What's new?.

Orbit (Amsterdam, Netherlands)

François Codère, Bernard Brais, Guy Rouleau, Edwin Lafontaine

Affiliations

  1. Departments of Ophthalmology, McGill University, Royal Victoria Hospital & University of Montreal, Montreal, Quebec, Canada

PMID: 12045902 DOI: 10.1076/orbi.20.4.259.2617

Abstract

The authors place autosomal dominant oculopharyngeal muscular dystrophy in a historical perspective, look at the genealogy involved, and review the genetic studies. In addition to summarizing what happens at the histopathological level, they examine the clinical characteristics of this late-onset dystrophy. Based on this knowledge, they try to present their rationale for the surgical treatment of the eyelid ptosis, taking into account that this disease is progressive and that treatment should be planned for the lifetime of the patient. Three representative cases are illustrated.

Publication Types